{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "regularMarketChangePercent": 0.8994963, "regularMarketPrice": 42.065, "marketState": "REGULAR", "regularMarketChange": 0.375, "regularMarketTime": 1684171780, "regularMarketDayHigh": 42.23, "regularMarketDayRange": "41.83 - 42.23", "regularMarketDayLow": 41.83, "regularMarketVolume": 130538, "regularMarketPreviousClose": 41.69, "bid": 42.09, "ask": 42.11, "bidSize": 10, "askSize": 12, "fullExchangeName": "NasdaqGS", "financialCurrency": "DKK", "regularMarketOpen": 41.85, "averageDailyVolume3Month": 481391, "averageDailyVolume10Day": 388670, "fiftyTwoWeekLowChange": 15.874998, "fiftyTwoWeekLowChangePercent": 0.6061473, "fiftyTwoWeekRange": "26.19 - 47.5", "fiftyTwoWeekHighChange": -5.4350014, "fiftyTwoWeekHighChangePercent": -0.114421085, "fiftyTwoWeekLow": 26.19, "fiftyTwoWeekHigh": 47.5, "trailingAnnualDividendRate": 0.0, "trailingPE": 32.86328, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": 1.28, "epsForward": 13.66, "exchange": "NMS", "shortName": "Genmab A/S", "longName": "Genmab A/S", "messageBoardId": "finmb_665704", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "firstTradeDateMilliseconds": 1243863000000, "priceHint": 2, "epsCurrentYear": 9.48, "priceEpsCurrentYear": 4.4372363, "sharesOutstanding": 652225024, "bookValue": 41.9769, "fiftyDayAverage": 38.7158, "fiftyDayAverageChange": 3.3491974, "fiftyDayAverageChangePercent": 0.086507246, "twoHundredDayAverage": 38.874725, "twoHundredDayAverageChange": 3.1902733, "twoHundredDayAverageChangePercent": 0.082065485, "marketCap": 27435845632, "forwardPE": 3.079429, "priceToBook": 1.0020988, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.6 - Hold", "tradeable": false, "cryptoTradeable": false, "symbol": "GMAB"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Kalvebod Brygge 43", "city": "Copenhagen", "zip": "1560", "country": "Denmark", "phone": "45 70 20 27 28", "website": "https://www.genmab.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.", "fullTimeEmployees": 1660, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jan G.J. van de Winkel Ph.D.", "age": 61, "title": "Co-Founder, Pres & CEO", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": {"raw": 2739160, "fmt": "2.74M", "longFmt": "2,739,160"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Anthony  Pagano", "age": 44, "title": "Exec. VP & CFO", "yearBorn": 1978, "fiscalYear": 2022, "totalPay": {"raw": 1019900, "fmt": "1.02M", "longFmt": "1,019,900"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Anthony  Mancini", "age": 51, "title": "Exec. VP & COO", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 1107320, "fmt": "1.11M", "longFmt": "1,107,320"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Martin  Schultz", "age": 46, "title": "Sr. Director of Clinical Operations  & Non-Independent Director", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": {"raw": 72850, "fmt": "72.85k", "longFmt": "72,850"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Judith V. Klimovsky M.D.", "age": 64, "title": "Exec. VP & Chief Devel. Officer", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": {"raw": 1151030, "fmt": "1.15M", "longFmt": "1,151,030"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Tahamtan  Ahmadi", "age": 49, "title": "Exec. VP, Chief Medical Officer & Head of Experimental Medicines", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": {"raw": 1092750, "fmt": "1.09M", "longFmt": "1,092,750"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Mijke  Zachariasse Ph.D.", "age": 48, "title": "Sr. Director, Head of Antibody Research Materials & Non-Independent Director", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": {"raw": 145700, "fmt": "145.7k", "longFmt": "145,700"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Takahiro  Hamatani", "age": 47, "title": "Sr. Director of Fin. Japan & Non-Independent Director", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": {"raw": 72850, "fmt": "72.85k", "longFmt": "72,850"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Andrew  Carlsen", "title": "Sr. Director, VP & Head of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Birgitte  Stephensen M.Sc.", "age": 61, "title": "Exec. VP & Chief Legal Officer", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 2, "boardRisk": 1, "compensationRisk": 3, "shareHolderRightsRisk": 1, "overallRisk": 1, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}